Showing results (171-180 of 178) with videos related to
Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.Nature|February 9, 2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.Pageof 18